causal
Small Rare Disease Markets Go Unserved Economically
Many small genetic disease markets with known mechanisms go unserved because a drug earning a few tens of millions a year cannot justify the $100 to $300 million development cost, so reducing trial costs would unlock valuable drugs.
causalpending
Speaker
AlexEvidence Quote
“there's a lot of, I think, alpha that could be unlocked in making the process much cheaper in how drugs are tested and validated”
Source
Alex Telford - Unlocking Innovation in Pharma - [Invest Like the Best, EP.360]— Invest Like the BestCreated: 11/14/2026, 6:42:06 AM
Your notes
Loading notes...